本港338萬人已打第三針 接種率達五成
港府公佈,截至週四(12日),約338萬人已完成接種第三劑新冠疫苗,佔12歲或以上人口的50%。
公務員事務局局長聶德權表示,目前約100萬人到期而尚未接種第三劑疫苗。因此,新冠疫苗接種計劃在過去兩週向相關人士發出超過100萬條電話短訊提醒。
他指,現時3歲或以上人口的第一劑和第二劑新冠疫苗接種率分別爲91.5%和85.6%;由於疫苗保護力會隨着時間有所減低,市民應按專家建議按時接種疫苗,以加強保護力。
「疫苗通行證」第三階段將於本月31日起實施,屆時所有適用的人士均須已接種第三劑疫苗(除個別特殊羣組外)。(ca/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.